You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-166-ESGO Prognostic signifience of molecular genetic factors in endometrial cancer. a modern approach to the problem
Free
  1. Irina Tripac1,
  2. Valentina Stratan2,
  3. Valeriu Tutuianu2,
  4. Victor Sitnic2,
  5. David Faraggi3 and
  6. Jean Calleja Agius4
  1. 1Gynaecology, Institute of Oncology, Chisinau, Moldova, Republic of
  2. 2Laboratory of Immunology and Molecular Genetics, Institute of Oncology, Chisinau, Moldova, Republic of
  3. 3University of Haifa, Haifa, Israel
  4. 4Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Malta, Malta

Abstract

Introduction/Background Modern methods of studying DNA structure, including cluster analysis, make it possible to determine the genetic profile of tumors.

Methodology The prospective study was performed on 50 patients with EC in stages I and II. The study design includes the description of the first stage of the study, marked by the evaluation of clinical-morphological features and the second stage marked by research of genetic features: determination of c.389G> A (p.R130Q) PTEN gene mutation.

Results The rate of the presence of the c.389G> A (p.R130Q) PTEN gene mutation is shown in all 4 subgroups of recurrence risk of patients with EC. The median survival time of patients with c.389G> A (p.R130Q) PTEN mutation was 15.7 ± 1.89 (95% CI [11.3–20.5]) months (95% CI 7–7 months), which did not differs (F = 0.005; p = 0.943) from mean time to progression in patients without mutations – 16.0 ± 3.97 (95% CI [12.0–28.0]) (figure 1). $$MISSING OR BAD GRAPHIC SPECIFICATION (2C128DE7-E0AB-4E14-ADC4–2A80097FE4FA) $$

Thus, the median survival time of patients in the low-risk group was 13.5 ± 3.37 (95% CI [9.0–18.0]) months, differing significantly from that in patients high risk – 15.8 ± 3.34 (95% CI [10.5–23.0]) months (F = 16.2; p = 0.891). Our research showed that group risk did not have an impact on the survival time of patients with PTEN mutation, this suggested that c.389G> A (p.R130Q) PTEN gene mutation may be regarded as a powerful prognostic factor for decreased survival time in patients with EC.

Abstract 2022-RA-166-ESGO Figure 1
Abstract 2022-RA-166-ESGO Figure 1

Overall survival in EC patients with or without c.389G> A (p.R130Q) PREN gene mutation

Conclusion This study showed that c.389G> A (p.R130Q) PTEN genetic mutation is strongly correlated with poor prognosis in EC patients. This may indicate that c.389G> A (p.R130Q) PTEN genetic mutation could be regarded as an important factor in the pathogenesis of EC. However, this finding is derived from small data in observational study, hence well conducted high-quality randomized trials are warranted.

https://doi.org/10.1136/ijgc-2022-ESGO.196

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.